Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172676 | 0.89 | CA14 (0.35) | SSTR4CA14 | |
| SCHEMBL15891326 | 0.87 | CA14 (0.37) | SSTR4CA14 | |
| SCHEMBL19560799 | 0.85 | CA14 (0.39) | SSTR4CA14 | |
| SCHEMBL30511000 | 0.84 | CA14 (0.41) | CA14 | |
| SCHEMBL14832112 | 0.84 | CA14 (0.41) | CA14 | |
| SCHEMBL30510997 | 0.84 | CA14 (0.41) | CA14 | |
| SCHEMBL25180272 | 0.83 | CA14 (0.35) | CA14 | |
| SCHEMBL9547222 | 0.83 | CA14 (0.35) | CA14 | |
| SCHEMBL16095967 | 0.83 | — | — | |
| SCHEMBL30373157 | 0.82 | CA14 (0.33) | SSTR4CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217319-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| CN-115925721-A | Pyrimidone tricyclic derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2023055827-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023277517-A1 | ACYCLIC NUCLEIC ACID MIMIC COMPRISING PENTACYCLIC BASE | 동아대학교 산학협력단 | 2023-01-05 | — | — | WO | disclosed |
| WO-2014151030-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | SSTR4 40/4885CA14 771/4885 |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | SSTR4 3634/4885CA14 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.